久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

上海非利加實業有限公司Logo

熱門詞: 進口電動溫度調節閥結構圖|進口電動溫度調節閥數據表進口電動高溫調節閥-德國進口電動高溫法蘭調節閥進口電動蒸汽調節閥-德國進口電動蒸汽調節閥

當前位置: 首頁 > 所有品牌 > Intercept Pharma
Intercept Pharma
Intercept Pharma Intercept Pharma

美國Intercept Pharma
Intercept Pharmaceuticals是一家生物制藥公司,公司在開發用于治療慢性肝纖維化和代謝性疾病治療方法方面正處于臨床階段。  
We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver disease utilizing our expertise in bile acid chemistry. Our product candidates have the potential to treat orphan and more prevalent liver diseases for which there currently are limited therapeutic solutions.

Our Lead Product Candidate

Our lead product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. OCA is a first-in-class product candidate that selectively binds to and induces activity in the farnesoid X receptor, or FXR, which we believe has broad liver-protective properties. We are developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to standard of care therapy and therefore need additional treatment. PBC is a chronic autoimmune liver disease that, if inadequately treated, may eventually lead to cirrhosis, liver failure and death. We are conducting a Phase 3 clinical trial of OCA in PBC, which we call the POISE trial, that we anticipate will serve as the basis for seeking regulatory approval in the United States and Europe. We expect results from the trial to be available in the second half of 2014. OCA has received orphan drug designation in the United States and Europe for the treatment of PBC.

We own worldwide rights to OCA outside of Japan and China, where we have exclusively licensed the compound to Dainippon Sumitomo Pharma, or DSP, and granted it an option to exclusively license OCA in certain other Asian countries. Patents covering the composition of matter for OCA expire in 2022, before any patent term adjustments or patent term extensions. Our current plan is to commercialize OCA in the United States and Europe ourselves for the treatment of PBC by targeting a limited and focused group of specialist physicians.

關于我們客戶服務產品分類法律聲明
主站蜘蛛池模板: 国产精品视频网站 | 日韩欧美色 | a国产在线 | 一级毛片视频免费 | 日韩精品第1页 | 高清 国产 日韩 欧美 | 影音先锋亚洲资源 | 日韩有码在线观看 | 国产精品网址 | 一区二区三区高清不卡 | 福利视频一区二区 | 国产精品久久久久影院色 | 国产高清一级在线观看 | 91在线精品亚洲一区二区 | 国产欧美综合在线一区二区三区 | 精品国产日韩一区三区 | 亚洲三级电影在线观看 | 国产原创91 | 最新国产网站 | 欧美1区二区三区公司 | 国产毛片一级 | 欧美成人中文字幕在线视频 | 国产精品高清久久久久久久 | 日韩高清在线高清免费 | 中文字幕精品一区二区精品 | 日韩亚洲第一页 | 国产精品久久久久久久9999 | 亚洲韩国日本欧美一区二区三区 | 日韩国产欧美一区二区三区 | 在线观看国产一区二区三区 | 欧美亚洲国产精品第一页 | 福利一区三区 | 在线免费观看国产精品 | 日本激情一区二区三区 | 国产日韩在线视频 | 99久久国产亚洲综合精品 | 欧美三级自拍 | 欧美日韩国产一区二区 | 91日韩| 偷拍第一页 | 91大神在线精品视频一区 |